Objectives: Gallbladder carcinoma (GBC) is the most highly aggressive cancer of biliary tract, but effective therapeutics are lacking. Emerging evidence has unveiled that miR-139-5p is aberrantly downregulated in cancers, including GBC. However, the functions and mechanisms of miR-139-5p in GBC remain unclear.
| INTRODUC TI ON
Gallbladder carcinoma (GBC) is the seventh malignant tumour in the gastrointestinal tract, as well as the most highly aggressive cancer in the biliary tract.
1 Although significant efforts have been made in basic research on GBC, the clinical outcomes of GBC patients have not improved due to late diagnosis, early metastasis, unsatisfactory treatment, and poor prognosis. 2, 3 In this regard, elucidating the molecular mechanisms underlying progression of GBC, which may have a critical role in the development of targeted GBC treatment, is extremely urgent.
Over the past few decades, numerous studies have demonstrated that the Warburg effect is a key hallmark of cancer cells. 4 Pyruvate kinase isozyme M2 (PKM2) is one of the isoforms of pyruvate kinase and a pivotal rate-limiting enzyme of glycolysis. 5, 6 Robust expression of PKM2 has been confirmed among diverse human cancers, such as gastric cancer, 7 colon cancer, 8 and GBC. 9 In addition, overexpressed PKM2 is associated with unfavourable prognosis in those patients.
10
High PKM2 expression is correlated with increased glucose uptake, upregulated lactate production, and reduced oxygen consumption which contribute to cancer cell proliferation and tumour growth.
11
However, the underlying causative mechanism of aberrant PKM2 expression in GBC is not clear. Several studies have confirmed that microRNAs (miRNAs) can regulate the expression of PKM2.
12,13
A growing body of evidence suggests that miRNAs carry out critical function in the progression of many human cancers. 14 MiRNAs are a set of small, noncoding RNAs of ~22 nucleotides which play a pivotal part in regulating gene expression by reducing posttranscriptional translation of target mRNAs. 15 The global alteration of their expression is a hallmark of tumourigenesis and can serve as a diagnostic and prognostic cancer signature. MiR-139-5p, with a length of 23 nt, is located within the second intron of the phosphodiesterase 2A gene on chromosome 11q13. 4 and is a common type of mature miRNA generated from miR-139 precursor. 15, 16 MiR-139-5p
has been discovered to be downregulated in various human tumours including glioblastoma multiforme, 17 bladder cancer, 18 hepatocellular carcinoma (HCC), 19 and breast cancer. 20 Overexpression of miR-139-5p inhibits the capacity of proliferation, invasion or metastasis of cancer cells. 21 Moreover, Pablo et al 22 had reported that the expression of miR-139-5p was significantly decreased in GBC tissues.
However, the functions and mechanisms of miR-139-5p in human GBC remain unclear.
Further study on the molecular mechanisms underpinning GBC energy metabolism and progression may provide novel targets and therapies to treat advanced GBC patients. In this study, we found that miR-139-5p played a pivotal role in GBC progression and metastasis by regulating PKM2. These results unravelled a novel and important mechanism for the regulation of anaerobic glycolysis and the development of GBC.
TA B L E 1 The relationship between miR-139-5p expression and clinicopathological features of GBC
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| MATERIAL S AND ME THODS
| Tissues and patients
Fifty-three paraffin-embedded tissues of GBC and 27 adjacent nontumour tissues (Zhengzhou cohort) were acquired between April 2009 and April 2014 from the First Affiliated Hospital of Zhengzhou University, China. All enrolled patients met the following criteria: (a) definite pathological diagnosis of GBC and (b) signed informed consent form before surgery. Tissue microarrays (TMA) using Zhengzhou cohort GBC tissues were constructed using 1.5-mm-diameter cores.
TMA containing 79 GBC specimens and 20 nontumour tissues (Outdo cohort) were purchased from Outdo Biotech (Shanghai, China). The clinicopathological data for these patients were presented in Table 1 .
The study was approved by the Institutional Review Board of the First Affiliated Hospital of Zhengzhou University.
| Cell lines and culture
The cell lines used in this study were shown in Table S1 . Cells were maintained in Dulbecco's modified Eagle medium (DMEM) with 10%
foetal bovine serum (FBS) (Gibco, Grand Island, NY, USA) mixing with 100 U/mL penicillin/streptomycin (Corning, New York, NY, USA) in a humidified atmosphere of 95% air and 5% CO 2 at 37°C. All cell lines used in this study were passaged for less than 6 months when the experiments were carried out.
| Transfection of miRNAs and siRNAs
Synthesized RNA duplexes of miR-139-5p mimics (miR-139-5p), inhibitors (anti-miR-139-5p) and PKM2 siRNAs (P-siRNA) as well as respective negative controls (NC) were commercially purchased from GenePharma (Shanghai, China). For cell transfection, 1 × 10 5 cells per well were seeded into the 12-well plates, and subse quently transfected with PKM2-siRNA, miR-139-5p mimics and inhibitor or negative control using LipoFiter (Hanbio, Shanghai, China) based on the manufacturer's protocol. RNA and protein were harvested 48 hours after transfection. The siRNA sequences used in this study were provided in Table S2 .
| RNA isolation and quantitative real-time PCR
Total RNA from GBC-SD and NOZ cells was extracted using 
| Western blotting
The procedure of Western blotting was performed as described previously. 23 Briefly, cells were collected and lysed using radio immu- incubation, the membranes were used to expose the photographic film. The antibodies used in this study are listed in Table S4 . 
| Wound-healing assay and transwell invasion assay
For the wound-healing assay, GBC-SD and NOZ cells (5 × 10 6 ) were seeded in six-well plates. When they had reached 80% confluence, a 200-μL sterile micropipette tip was used to form a 1 mm wide strip across the well. The cells migrating into the wounded areas were visualized and photographed at 0 and 48 hours after washing the well with PBS.
For the cell invasion assay, transwell matrigel chambers coated with matrigel (BD Biosciences, Franklin Lakes, NJ, USA) were used. 
| Immunohistochemical staining and in situ hybridization on TMA
Immunohistochemical (IHC) staining was performed according to the method described in a previous study. 23 Briefly, TMA sections were deparaffinized, rehydrated, and antigen retrieval was per- Table S4 .
| Immunofluorescence analysis
Immunofluorescence (IF) staining was performed according to the method described in a previous study. 23 Briefly, cells were washed with 1× PBS, fixed with 4% paraformaldehyde and permeabilized with 0.5% Triton X-100 (Solarbio, Shanghai, China). After blocking with 5% goat serum, the cells were incubated with primary antibody (PKM2 and β-actin; Proteintech Group) at 4°C overnight and then incubated with the appropriate secondary antibodies (Jackson ImmunoResearch Inc., USA). The nuclei were counterstained with DAPI (Beyotime, China), and the IF signals were detected using a Zeiss-AX10 microscope (Zeiss, Oberkochen, Germany). The information of antibodies used in this study is listed in Table S4 .
| Luciferase activity assay
The 3′UTR (3′ untranslated region) sequence of PKM2 containing the Reporter Assay System (Promega) by the manufacturer's protocols.
The primer sequence used in this study provided in Table S3 .
| Vector construction and lentiviral transduction
The coding sequences of human miR-139-5p were amplified and cloned into pcDNA3.1 (+) to generate miR-139-5p expression vectors (GenePharma, Shanghai, China). An empty pcDNA3.1 vector was used as the negative control. GBC-SD cells (1 × 10 5 ) were infected with a lentivirus encoding miR-139-5p mimics or an empty lentivirus for 96 hours and then selected by treatment with puromycin (Santa Cruz Biotechnology) for 4 weeks.
| Glucose, oxygen consumption, and lactic acid assays
Glucose consumption was accessed using a glucose oxidase- 
| Glycolysis stress test
Measurements of the extracellular acidification rate (ECAR) and oxygen consumption rate (OCR) were performed to assess the effect of miR-139-5p overexpression on glycolysis stress and cell mitochondrial stress using the Seahorse XF96 Glycolysis Analyser (Seahorse Bioscience, Billerica, MA, USA). For ECAR analysis, glucose, oligomycin, and 2-deoxyglucose were sequentially added in special medium. First, glucose was injected into the medium, catabolized to lactate and ATP, with a corresponding increased ECAR value.
Then, oligomycin was injected, which inhibited mitochondrial ATP production and shifted the energy production to glycolysis, with the corresponding increase in ECAR. The ECAR is reported in milli-pH 
| Tumour xenograft experiments
| Statistical analysis
Statistical analyses were performed using SPSS software (version 23.0; SPSS Inc., Chicago, IL, USA). All experiments were repeated at least three times to calculate the mean and standard deviation (SD). Clinicopathological variables were analysed by chi-square tests.
Kaplan-Meier curves and log-rank tests were used to analyse the OS of GBC patients. To identify the factors that had a significant influence on survival, univariate and multivariate Cox regression analyses were performed. Student's t test was used for comparison between two groups. P (two-sided) values less than 0.05 were statistically significant. Data were presented as the mean ± standard deviation (SD).
| RE SULTS
| MiR-139-5p was inversely associated with clinicopathological features in patients with GBC
To explore whether miR-139-5p was dysregulated in GBC, we first analysed miR-139-5p expression levels in an independent GBC datasets (GSE90001, four GBC tissues and four normal tissues) from the Gene Expression Omnibus (GEO) database. The results showed that miR-139-5p expression was downregulated in GBC tissues ( Figure 1A ). We further used ISH to measure miR-139-5p status in 123 GBC tissues and 43 adjacent normal gallbladder samples from GBC patients. We observed that the expression level of miR-139-5p
was downregulated in GBC tissues compared with that in nontumour gallbladder tissues (P = 0.0212; Figure 1B ). According to staining intensity and the percentage of positive cells in the tissue sections, we categorized miR-139-5p staining patterns into four groups, as shown in Figure 1C . We found the expression level of miR-139-5p was negatively correlated with tumour stages (P < 0.0001; Figure 1D ) and the presence of metastasis (P = 0.0468; Figure 1E ). Moreover, KaplanMeier analysis demonstrated a statistically significant negative relationship between overall survival (OS) and miR-139-5p expression levels ( Figure 1F) . A detailed summary of the relationships between miR-139-5p expression and the clinicopathological features of GBC patients is shown in Table 1 .
In addition, univariate Cox proportional hazards analysis of OS exhibited that miR-139-5p expression, distant metastasis, pathological grade, and TNM stage were important prognostic factors ( Figure 1G and with GBC. In conclusion, these data suggested that miR-139-5p might play a pivotal role in the progression and development of human GBC.
| Overexpression of miR-139-5p inhibited in vitro GBC cell proliferation, migration, and invasion
Considering the notable association between miR-139-5p and aggressive GBC features, we postulated that re-expression of miR-139-5p in GBC cells could impede the proliferation and invasiveness of GBC cells. To investigate this possibility, we first detected the role of miR-139-5p in GBC cell proliferation. MTT assays presented that overexpression of miR-139-5p significantly reduced the viability of GBC-SD and NOZ cells (Figure 2A,B) . Consistently, the colony formation assay showed that overexpression of miR-139-5p promisingly suppressed the growth capacity of GBC cells ( Figure 2C,D) .
Additionally, EdU assays indicated that miR-139-5p-overexpressing GBC cells had lower proliferative activity than the control cells ( Figure 2E,F) . Next, we further evaluated the role of miR-139-5p in the migration and invasion of GBC cells and found that migration and invasion of GBC cells were significantly inhibited after miR-139-5p overexpression ( Figure 2G-J) . Thus, these data implied that miR-139-5p served as a tumour suppressor which could inhibit the proliferation, migration, and invasion of GBC cells.
| PKM2 as the functional target of miRNA-139-5p
We next investigated the potential gene targets of miR-139-5p that contributed to its tumour suppressor function. Online miRNA database analysis (TargetScan, miRanda and PicTar) indicated that PKM2 could be a target of miR-139-5p according to the putative target sequence in the PKM2 3′UTR ( Figure 3A) . Western blot and qRT-PCR analysis were conducted to further identify whether PKM2 expression was indeed regulated by miR-139-5p.
The results showed that the protein and mRNA levels of PKM2
were significantly reduced after transfecting miR-139-5p mimics in GBC cells ( Figure 3B,C) . Subsequently, luciferase reporter assay was conducted, and we found that the signal from the luciferase reporter fused with the wild-type 3′UTR fragments of the PKM2 mRNA was significantly decreased compared with that from the mutant vector, demonstrating the specificity of the interaction between miR-139-5p and the mRNA 3′-UTR of PKM2 ( Figure 3D ).
These results suggested that miR-139-5p could directly target PKM2 and negatively regulate PKM2 expression.
| PKM2 silencing inhibited the proliferation and invasion of GBC cells by repressing aerobic glycolysis
To investigate the role of PKM2 in the progression of GBC, we first used IF to determine the location of PKM2 in GBC cells and found that PKM2 were mostly distributed in cell cytoplasm of GBC cells ( Figure 3E ). We then examined the relative protein levels of PKM2 in four GBC cell lines by Western blot ( Figure 3F ) and chose GBC-SD and NOZ cell lines for following 
| PKM2 was overexpressed in GBC tissues and negatively correlated with OS
To further confirm PKM2 expression in GBC, we examined PKM2 expression in GBC samples and normal tissues using IHC. Brown cytoplasmic PKM2 staining was relatively high positive in GBC tissues but nearly absent from normal epithelia (P=0.0059; Figure 4A ,B).
Additionally, there was a strong positive relationship between PKM2 and the tumour proliferation marker Ki-67 staining score, as shown in Figure 4C . The expression levels of PKM2 were significantly higher in the late TNM stage (P = 0.0019; Figure 4D ) and in tumours in which metastasis was present (P = 0.0468; Figure 4E ). Moreover, in GBC patients, increased PKM2 immunoreactivity was accompanied by significantly poor postoperative survival (P = 0.0002; Figure 4F ).
Additionally, there was a notable negative correlation between the expression level of PKM2 and miR-139-5p ( Figure 4G ). These results indicated that GBC patients with high PKM2 expression possessed poorer prognosis than those with low PKM2 expression.
| The miR-139-5p/PKM2 axis regulated glucose metabolism in GBC cells
Considering the important roles of PKM2 in GBC cell metabolism,
we further determined the function of miR-139-5p in glycolysis.
We observed that miR-139-5p-overexpressing GBC cells consumed less glucose ( Figure 5A ) and exhibited lower lactate production ( Figure 5B ) and cellular ATP levels ( Figure 5C ) than the control cells.
Inhibition of miR-139-5p caused a dramatic elevation in glucose consumption, lactate production, and cellular ATP level in GBC cells ( Figure 5A-C) . Furthermore, restoration of PKM2 protein in GBC cells diminished the inhibitory effects of miR-139-5p on glucose consumption, lactate production, and ATP level ( Figure 5D-F) , implying that miR-139-5p might involve in glycolysis by regulating PKM2 expression in GBC cells.
To further assess whether miR-139-5p modulates glucose metabolism of GBC cells, the glycolytic flux was first analysed based on ECAR using the Seahorse assay. We observed a significant de- Impressively, these data suggested that miR-139-5p overexpression caused severe defects in glycolysis and caused an increase in mitochondrial function.
| miR-139-5p overexpression suppressed GBC tumour proliferation in vivo
To explore the in vivo effects of miR-139-5p on GBC growth, 
| D ISCUSS I ON
MiRNAs are involved in multiple tumourigenesis processes, and understanding the biological functions of miRNAs in regulating a series of tumour suppressor genes and oncogenes is a new avenue for research. 24, 25 MiRNA-139-5p is known to be dysregulated in several cancers. 16, 26, 27 However, the biological functions and mechanisms of miR-139-5p in GBC are unknown. Warburg effect has been implicated in gallbladder tumourigenesis. 28, 29 Emerging evidence has also indicated an association between miRNA dysregulation in general, and Warburg effect in particular, during cancer development.
30,31
In our study, we identified that miR-139-5p was significantly downregulated in GBC tissues and was negatively associated with malignancies. Further functional analyses revealed that overexpression of miR-139-5p led to significant suppression of cell prolif- 35 Additionally, miR-139-5p was significantly higher in peripheral blood from prostate cancer (PCa) patients and was positively associated with progression of PCa. 36 MiRNAs have been identified to function as either tumour suppressors or oncogenes depending on the cell or cancer type in which they are expressed.
For instance, miR-155 might function as a tumour suppressor in pancreatic cancer, 37 while it has oncogenic activity in B-cell lymphomas. 38 Thus, taking these findings together, miR-139-5p also appears to play a dual role as both a main tumour-suppressing and secondary tumour-promoting miRNA. by targeting ELTD1 and regulating cell cycle. 40 However, the mechanisms underlying the functional role of miR-139-5p in GBC were largely unknown.
Bioinformatics analysis and luciferase reporter assays demonstrated that PKM2 was a direct target of miR-139-5p. In addition, an inverse correlation between the expression levels of miR-139-5p and PKM2 was also observed in our GBC TMA cohort. PKM2 is known as a molecular switching for aerobic glycolysis (Warburg effect), and has a critical role in essential processes of glucose metabolism in cancer cells. 5 Increased expression of PKM2 has been found in diverse human cancers and leads to metabolic reprogramming in cancer cells. 41 Thus, PKM2 has become a potential target for therapeutics. Accordingly, our data indicated that PKM2 was overexpressed in GBC tissues. PKM2 overexpression was associated with malignancies and poor overall survival, consisting with the results of Li et al. and Lu et al 9, 42 who both identified that high PKM2 expression was significantly related to poor prognosis in GBC. Additionally, our data indicated that PKM2 knockdown potently inhibited GBC cell proliferation and invasion through repressing glucose metabolism. This was in agreement with previous studies of PKM2 in other cancer types.
43,44
In a subsequent mechanistic experiment, we investigated whether miR-139-5p inhibited the progression of GBC by suppressing PKM2-mediated glycolysis. Our findings exhibited that miR-139-5p could suppress glucose metabolism of GBC cells. In summary, the present study revealed that miR-139-5p was downregulated and negatively associated with malignancies in GBC.
MiR-139-5p significantly inhibited GBC proliferation, invasion, and glucose metabolism by targeting PKM2. These results provided a better understanding of the mRNA-miRNA feedback loop function in the glucolysis of GBC. MiR-139-5p may be considered as a biomarker for GBC progression and a potential target for therapeutic intervention for GBC.
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